PHYLLIS ASELTINE: Open Payments
NPI 1376545251 · SOUTH SALT LAKE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$833 in 11 payments from 8 companies in 2025. Trend: 2023 $805 · 2024 $1,340 · 2025 $833
Food & beverage: $833
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 2 | $244 |
| Mallinckrodt Hospital Products Inc. | 1 | $146 |
| Apellis Pharmaceuticals, Inc. | 1 | $139 |
| AKEBIA THERAPEUTICS INC | 1 | $107 |
| Amgen Inc. | 2 | $67 |
| Vantive US Healthcare LLC | 1 | $64 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $32 |
Products named: TERLIVAZ, IBSRELA, XPHOZAH 30 MG, Vafseo, Renal - Chronic, TAVNEOS, Fabhalta, VELPHORO.
Industry payments across UT — which companies pay providers there.
